Biotech Stock Sitting Out Today's Rally

REGN has seen two bear notes in as many trading days

Digital Content Manager
Oct 17, 2022 at 10:27 AM
facebook twitter linkedin

While the rest of the market is making moves higher today, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is static, last seen off 0.1% at $735.31. Evercore downgraded REGN to "in-line" from "outperform" today, not even one trading day removed from Cantor Fitzgerald lowering its full-year 2022 profits and sales estimates on Friday. The biotech drugmaker will report earnings before the open on Nov. 3. 

On Friday, REGN surged to its highest level on record, hitting $761.04 before plummeting to a loss by the close. The stock boasts a 15.8% year-to-date lead though, and since a Sept. 8 bull gap, has relied on support from its ascending 20-day moving average.

Overall analyst sentiment shows a mixed brokerage bunch. Of the 19 in coverage, 11 say "buy" or better, while eight say "hold" or worse. Meanwhile, the 12-month consensus price target of $759.65 is a slim 3.6% premium to current levels.

Options traders, meanwhile, have taken a more bearish stance. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), REGN sports a 50-day put/call volume ratio of 1.02, which sits in the 94th percentile of its annual range. In other words, long puts have rarely been more popular.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners